Table 1.
Study Subjects in Gene Expression Analyses
| Characteristic | COPDGene (N = 3,618) | ECLIPSE (N = 646) |
|---|---|---|
| Age, yr | 64.90 [58.20–71.80] | 64.00 [59.00–69.00] |
| Female sex | 1,767 (48.8) | 222 (34.4) |
| Race | ||
| Non-Hispanic White | 2,615 (72.3) | 638 (98.8) |
| African American | 1,003 (27.7) | 8 (1.2) |
| BMI, kg/m2, median [IQR] | 28.08 [24.57–32.28] | 26.68 [23.36–29.98] |
| Current smoker | 1,360 (37.6) | 160 (24.8) |
| Smoking history, pack-years | 40.00 [27.50–54.80] | 41.00 [28.00–56.00] |
| COPD status | ||
| PRISm | 473 (13.1) | 0 |
| Normal spirometry | 1,571 (43.4) | 0 |
| GOLD stage | ||
| 1 | 363 (10.0) | 0 |
| 2 | 703 (19.4) | 270 (46.1) |
| 3 | 360 (10.0) | 243 (41.5) |
| 4 | 148 (4.1) | 73 (12.5) |
| FEV1/FVC | 0.72 [0.61–0.78] | 0.46 [0.37–0.57] |
| FEV1% predicted after bronchodilation | 82.00 [63.30–95.77] | 50.25 [37.88–65.65] |
| History of exacerbation | 616 (17.0) | 256 (39.6) |
| History of severe exacerbation | 328 (9.1) | 83 (12.8) |
| Persistent exacerbators | 291 (8.9)* | 278 (43.0) |
| Prospective exacerbation rate per year | 0.00 [0.00–0.25] | 0.67 [0.00–2.00] |
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; COPDGene = Genetic Epidemiology of COPD; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; PRISm = preserved ratio impaired spirometry (FEV1/FVC ⩾ 0.70, FEV1% predicted <80%); GOLD = Global Initiative for Chronic Obstructive Lung Disease; NA = not available.
Values presented as number (percentage) or median [IQR]. History of exacerbation refers to self-reported exacerbation during 1 yr before study visit. Severe exacerbation was defined as any exacerbation requiring an emergency room visit or hospital admission. Persistent exacerbators were defined as those who have at least one exacerbation per year in the follow-up years.
Excluding 356 subjects without longitudinal follow-up data.